Subsequent proteomics revealed that <b>10</b> targets NOS2 to modulate Alzheimer's disease (AD)-associated pathways and the KEAP1-NRF2 axis. This evidence concerns the gene KEAP1 and early-onset autosomal dominant Alzheimer disease.